THQM — Tchaikapharma High Quality Medicines AD Income Statement
0.000.00%
Last trade - 00:00- €872.69m
- €878.21m
- BGN64.00m
Annual income statement for Tchaikapharma High Quality Medicines AD, fiscal year end - December 31st, BGN millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 42.6 | 43.2 | 48.6 | 53.3 | 64 |
| Cost of Revenue | |||||
| Gross Profit | 11.8 | 12.4 | 15 | 17.6 | 21.2 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 41.1 | 40.8 | 44.6 | 48.1 | 57.1 |
| Operating Profit | 1.46 | 2.33 | 3.97 | 5.17 | 6.94 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 1.57 | 3.13 | 3.87 | 5.03 | 7.09 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.4 | 2.79 | 3.4 | 4.49 | 6.43 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.4 | 2.79 | 3.4 | 4.49 | 6.43 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.4 | 2.79 | 3.4 | 4.49 | 6.43 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.001 | 0.002 | 0.003 | 0.047 | 0.067 |
| Dividends per Share |